Jet-delivered DNA vaccine to clear HPV16/18 cervical infections
Jet vaccination with pBI-11 DNA to treat HPV16/18+ ASC-US/LSIL
This project uses a jet-delivered DNA vaccine to help people with persistent HPV16 or HPV18 infections and mild abnormal Pap results (ASC-US/LSIL) clear the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11191603 on NIH RePORTER |
What this research studies
You would be offered a therapeutic DNA vaccine (pBI-11) delivered using a needle-free jet device to stimulate your immune system to target HPV16/18. The team plans to enroll people with persistent HPV16/18 and low-grade abnormal cervical screening results and follow them with HPV testing, Pap/colposcopy as needed, and biopsies to monitor response. The goal is to eliminate the infection before it progresses to high-grade lesions that require surgery. Treatment and frequent follow-up visits would take place at the clinical site and include monitoring for safety and immune responses.
Who could benefit from this research
Good fit: Ideal candidates are people with persistent HPV16 or HPV18 infection detected on cervical screening who have ASC-US or LSIL and no high-grade (CIN2/3) disease.
Not a fit: People who already have high-grade cervical lesions (CIN2/3), invasive cancer, infections from other HPV types, or certain severe immune problems may not benefit from this intervention.
Why it matters
Potential benefit: If successful, the vaccine could clear persistent HPV16/18 infections, lower the chance of progression to high-grade lesions, and reduce the need for surgical treatment.
How similar studies have performed: Previous therapeutic HPV vaccine approaches have produced some encouraging immune responses and occasional lesion regression in small trials, but vaccine therapy for clearing HPV16/18 in this early-screening setting remains experimental.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Hung, Chien-Fu — Johns Hopkins University
- Study coordinator: Hung, Chien-Fu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.